Replies to post #216618 on Biotech Values

[Titan V]

I would avoid RXII at all costs.

- did its 3rd(!) reverse split last week
- delayed dermal scarring results over a year, doing new cohorts every time
- their “cosmeceutical” program was billed as being a cash cow with big pharma interest. However, the head of the program, Pamela Pavco, “retired” before any data
- they said a list of companies were in the short list to partner with them. However, they ended up “partnering” with MirImmune, management of which are friends/have history with CEO Geert Cauwenberg. Then they acquired this company. CEO of MirImmune became CBO of RXI and then he also resigned from his post later in 2017
- History of empty promises and exaggerations

I got in this stock with free shares from GALE spinoff. Bought some more few years ago as well. Biggest mistake of my investing career. Nevertheless it has taught me to spot many biotech red flags. I anticipate a fourth reverse split in about 18 months. This is the DRYS of biotech.